Rigor Reviewed

Rigor-Reviewed Manuscript

External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial.

Name: Αlpha¹ Rigor Record — External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial.
Item: External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial.
Rating: 100
Author: Αlpha¹

Conti AA, Bozhilova N, Eraydin IE, Stringer D, Johansson L, Marhenke R, Bilbow A, El Masri S, Hyde J, Giaroli G, Liang H, Fiori F, Mehta MA, Santosh P, Carter B, Cortese S, Rubia K

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 3 high issues for “External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Declared data/code links were not checked for liveness or content.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized sham-controlled trial. The methods are rigorous, ethical approvals are documented, and data are publicly available. Minor reporting inconsistencies and an overstated claim in the discussion are the main weaknesses.

Both reviewers independently scored all dimensions as pass with high confidence; no divergence. The study is an interventional RCT; non-applicable criteria (e.g., animal housing, cell lines) were excluded. Statistics verification covered only 2 tests; other reported statistics were not machine-verified.

5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites the pilot RCT (McGough et al.) and a meta-analysis of TNS safety, and explains the need for a definitive multicenter trial. It also addresses limitations of prior work, such as the pilot's short duration and narrow age range, and describes how the current study addresses these gaps. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research, including the pilot RCT that led to FDA clearance, and provides a logical rationale for the confirmatory trial.

Evidence

paraphrase[Introduction, paragraph 3]

“Our recent meta-analysis showed that TNS is safe with good tolerability for neurological and psychiatric conditions.”

paraphrase[Introduction, paragraph 4]

“Furthermore, the pilot study did not assess effects beyond 4 weeks and was limited to very young children aged 8−12 years.”

direct quote[Introduction, paragraph 4]

“We hypothesized that 4 weeks of nightly real versus sham TNS in children and adolescents with ADHD would improve core symptoms, as measured by parent-rated scales (primary outcome).”